TNG_CFD

Transgene SA

Transgene SA is a biotech firm that specializes in developing innovative immunotherapies for cancer and infectious diseases. Their proprietary technology platform creates genetically modified viruses that selectively target and destroy cancer cells while leaving healthy cells unharmed. Their lead product candidate, TG4010, is a therapeutic vaccine for non-small cell lung cancer that has shown promising results in clinical trials. Transgene has a pipeline of other immunotherapies in development, including treatments for hepatitis B and solid tumors. With a team of experienced scientists and a commitment to advancing immunotherapy, Transgene is dedicated to improving the lives of patients with serious diseases.

Prietaiso specifikacijaTransgene SA

Scroll to top